Breaking Down the Phase 2 Obesity Results: What the Numbers Actually Mean

The Headline Number

When the retatrutide Phase 2 obesity results were presented at ADA 2023 and published simultaneously in the New England Journal of Medicine, one number dominated the coverage: 24.2% mean weight loss at the highest dose (12 mg) after 48 weeks. Here is what that number means, what the data behind it look like and where the caveats are.

Understanding the Study Design

Before reading the results, it helps to know how the study was built. The trial enrolled 338 adults with obesity (BMI ≥30) or overweight with comorbidities (BMI ≥27+) across U.S. sites. Participants were randomized to placebo or one of five retatrutide dose groups. The study was double-blind, meaning neither participants nor investigators knew who received active drug versus placebo.

Treatment lasted 48 weeks, which is fairly standard for a Phase 2 obesity trial but shorter than many Phase 3 programs (which usually run 68-72 weeks). This matters because weight loss had not fully leveled off at week 48, which suggests the maximum effect had not yet been reached.

Dose-Response: A Clear Gradient

One of the most useful features of the data was the clear dose-response:

• 1 mg: -8.7%
• 4 mg (two sub-arms, starting at 2 mg or 4 mg, pooled): -17.1%
• 8 mg: -22.8%
• 12 mg: -24.2%
• Placebo: -2.1%

This gradient matters for several reasons. First, it shows that the drug, not chance, is causing the effect. Second, it guided the choice of doses for Phase 3. Third, the fairly small gap between 8 mg (-22.8%) and 12 mg (-24.2%) suggests the dose-response curve was flattening but had not clearly leveled off.

The Escalation Effect

The 4 mg and 8 mg targets were each tested with two starting doses, 2 mg and 4 mg, and doses were raised every 4 weeks. The published results pool each pair. The -12.9% sometimes quoted for a “fixed 4 mg” arm is the pooled 4 mg result at 24 weeks; the pooled 4 mg result at 48 weeks was -17.1%. There was no fixed-dose 4 mg arm to compare against.

Responder Analysis: Beyond Averages

Average weight loss can mislead if a few extreme responders pull the figure up. The responder analysis adds important context. In the 12 mg group:

• 100% lost at least 5% body weight
• 93% lost at least 10%
• 83% lost at least 15%
• 73% lost at least 20%
• 50% lost at least 25%

The response was strikingly consistent. Essentially every participant at the highest dose reached clinically meaningful weight loss, and most passed thresholds usually linked to bariatric surgery results. This is not a case of a few super-responders pulling up the average; the benefit was broadly distributed.

What About Placebo?

The placebo group lost 2.1% of body weight, which is typical for obesity trials (participants often make some behavioral changes just by enrolling in a clinical trial). The gap between placebo and active treatment, more than 22 percentage points at the highest dose, gives strong confidence that the drug caused the effect.

Liver Fat: The Surprise Finding

Weight loss was the primary endpoint, but the liver fat data from the MRI-PDFF substudy may prove just as important. The approximately 82% relative reduction in liver fat at the highest dose was far more than weight loss alone would predict. It points to a direct effect of the glucagon receptor component on how the liver handles fat. For a disease (MASLD) that affects roughly 25% of adults worldwide and has almost no approved treatments, this opens a significant new treatment route.

Safety: The Other Side of the Coin

Efficacy always has to be weighed against safety:

• GI adverse events (nausea, diarrhea, vomiting) were the most common side effects
• Most were mild to moderate and occurred during dose escalation
• Discontinuation due to adverse events ranged from 6% to 16% across the retatrutide groups (7% at 1 mg, 16% at 12 mg), with none on placebo
• No unexpected or serious safety signals emerged

The 16% discontinuation rate at the highest dose is notable and worth watching in Phase 3. Better dose-escalation schedules may lower it.

Key Caveats

Several important limits should temper how these results are read:

Phase 2 vs. Phase 3: Phase 2 trials are smaller, populations are more selected, and sites are typically fewer. Effect sizes sometimes diminish in the larger, more diverse Phase 3 setting.

Duration: 48 weeks is shorter than the 68-72 weeks typical of pivotal obesity trials. The continuing weight loss suggests the 48-week results understate the maximum effect, but this is unconfirmed.

U.S. only: The trial was conducted entirely at U.S. sites, limiting generalizability to other populations.

No active comparator: The trial compared retatrutide to placebo only, not to semaglutide, tirzepatide, or other agents. Cross-trial comparisons are informative but not definitive.

What Comes Next

The Phase 3 TRIUMPH program will address these limits with more participants, longer treatment, global sites and possibly active comparator arms. The central question is simple: will the Phase 2 results hold up? If they do, retatrutide will have set a new standard for weight loss drugs.

Update, October 2026: the Phase 3 trials have now reported. TRIUMPH-1 found 28.3% mean weight loss at 12 mg over 80 weeks and TRIUMPH-4 found 28.7% over 68 weeks, and the active-comparator trial TRANSCEND-T2D-2 reported against semaglutide in October 2026. See Retatrutide’s Published Trials, Explained.

For now, the Phase 2 data are the strongest efficacy signal ever seen for an obesity drug, with the caveat that Phase 3 confirmation is still essential.